BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu M, Xie K, Lu X, Lu L, Shi Y, Tang Y. Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling. Invest New Drugs 2021;39:416-25. [PMID: 33128383 DOI: 10.1007/s10637-020-01027-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Li S, Pi G, Zeng Y, Ruan C, He X, Xiong X, Zhang M, Zou J, Liang X. Notoginsenoside R1 induces oxidative stress and modulates LPS induced immune microenvironment of nasopharyngeal carcinoma. International Immunopharmacology 2022;113:109323. [DOI: 10.1016/j.intimp.2022.109323] [Reference Citation Analysis]
2 Gao Q, Cui L, Huang C, Zhou C, Chen B, Wang Q, Chen Z, Zhao Y, Wang M, Shen B, Xu W, Zhu W. Gastric cancer-derived exosomes induce PD-L1 expression on human bone marrow mesenchymal stem cells through the AKT-c-Myc signal axis. All Life 2022;15:442-51. [DOI: 10.1080/26895293.2022.2058098] [Reference Citation Analysis]
3 Xu H, Zhang X, Shi Y, Yu K, Jiang Y. Notoginsenoside R1 relieves the myocardial infarction via activating the JAK2/STAT3 signaling pathway in vivo and in vitro. Bioengineered 2022;13:5653-62. [PMID: 35263202 DOI: 10.1080/21655979.2022.2037366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang S, Wang Y, Huang Z, Wei H, Wang X, Shen R, Lan W, Zhong G, Lin J. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway. Acta Biochim Biophys Sin (Shanghai) 2021;53:1670-80. [PMID: 34693451 DOI: 10.1093/abbs/gmab146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
5 Sarhadi VK, Daddali R, Seppänen-Kaijansinkko R. Mesenchymal Stem Cells and Extracellular Vesicles in Osteosarcoma Pathogenesis and Therapy. Int J Mol Sci 2021;22:11035. [PMID: 34681692 DOI: 10.3390/ijms222011035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Ni Y, Zhou X, Yang J, Shi H, Li H, Zhao X, Ma X. The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment. Front Cell Dev Biol 2021;9:637675. [PMID: 34095111 DOI: 10.3389/fcell.2021.637675] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
7 Mirzaei S, Zarrabi A, Hashemi F, Zabolian A, Saleki H, Azami N, Hamzehlou S, Farahani MV, Hushmandi K, Ashrafizadeh M, Khan H, Kumar AP. Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery. Antioxidants (Basel) 2021;10:349. [PMID: 33652780 DOI: 10.3390/antiox10030349] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 14.5] [Reference Citation Analysis]